ORM PTO-1390 (Modified) U.S. PATENT AND TRADEMARK OFFICE; U.S. DEPARTMENT OF COMMERCE PP022717.0004 TRANSMITTAL LETTER TO THE UNITED STATES U.S. APPLICATION NO. (If known, see 37 CFR 1.5) DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A SUBMISSION UNDER 35 U.S.C. 371 INTERNATIONAL APPLICATION NO. INTERNATIONAL FILING DATE 17 March 2004 17 March 2005 PCT/IB2005/000987 TITLE OF INVENTION ANALYSIS OF SACCHARIDE VACCINES WITHOUT INTERFERENCE APPLICANT(S) FOR DO/EO/US Angela BARDOTTI, Daniela PROIETTI and Stefano RICCI Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information: This is a FIRST submission of items concerning a submission under 35 U.S.C. 371. 1. 2. This is a SECOND or SUBSEQUENT submission of items concerning a submission under 35 U.S.C. 371. This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), 3. (9) and (24) indicated below. The US has been elected (Article 31). 4. 5. A copy of the International Application as filed (35 U.S.C. 371 (c)(2)) a. 🗆 is attached hereto (required only if not communicated by the International Bureau). b. 🛛 has been communicated by the International Bureau. c. 🗆 is not required, as the application was filed in the United States Receiving Office (RO/US). An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)). 6. а. 🗆 is attached hereto. b. 🗆 has been previously submitted under 35 U.S.C. 154(d)(4). 7. Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371 (c)(3)) are attached hereto (required only if not communicated by the International Bureau). b. 🗆 have been communicated by the International Bureau. have not been made; however, the time limit for making such amendments has NOT expired. C. d. 🗆 have not been made and will not be made. An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)). 8. 9.  $\Box$ An oath or declaration of the inventor(s) (35 U.S.C. 371 (c)(4)). An English language translation of the annexes to the International Preliminary Examination Report under PCT 10. Article 36 (35 U.S.C. 371 (c)(5)). A copy of the International Preliminary Examination Report (PCT/IPEA/409).  $\boxtimes$ A copy of the International Search Report (PCT/ISA/210). Items 13 to 23 below concern document(s) or information included: 13. An Information Disclosure Statement under 37 CFR 1.97 and 1.98. 14. An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. 15.  $\boxtimes$ A FIRST preliminary amendment. A SECOND or SUBSEQUENT preliminary amendment. 16. 17. A substitute specification. 18 A power of attorney and/or change of address letter. 19. A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 CFR 1.821 - 1.825.  $\times$ A second copy of the published International Application under 35 U.S.C. 154(d)(4). 20. A second copy of the English language translation of the International Application under 35 U.S.C. 154(d)(4). 21.  $\boxtimes$ 22. Express Mail Label No. EL987062178US  $\boxtimes$ 23. Other items or information:

copy of unsigned Declaration for Patent Application

## IAP16 Rec'd PCT/PTO 14 SEP 2006

PTC-1390 (Rev. 12-2004)

Approved for use through 3/31/2007. OMB 0651-0021

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE ction Act of 1995. no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Order the Paperwork Reduction Act of 1995, no persons are required to respond to a conection of milotimatic						E TOTAL CONTROL OF THE TOTAL C	ONB CONTO HUMBER	
U.S. APPLICATION NO. (if known, see 37 CFR 1.5)  INTERNATIONAL APPLICATION NO.  PCT/IB2005/000987			ICATION NO.	ATTORNEY'S DOC	KET NUMBER			
			00987	PP022717.0004				
24. The following fees are submitted:						Applicant use	Office use	
☐ a) Basic national fee						\$ \$300.00		
⊠             b) Examination fee						\$ \$200.00		
⊠ c) Search fee						\$ \$500.00		
TOTAL OF ABOVE CALCULATIONS = \$1000.00						\$ \$1,000.00		
Additional fee for specification and drawings filed in paper over 100 sheets (excluding sequence listing or computer program listing filed in an electronic medium). The fee is \$250 for each additional 50 sheets of paper or fraction thereof.								
Total Sheets	Extra Sheets	of each additional 50 or eof (round up to a whole				,		
29 - 100 =	-71 /50 =		-1		x	\$ \$0.00		
Surcharge of \$130.00 for furnishing the oath or declaration later than months from the earliest claimed priority date (37 CFR 1.492(e)).						\$ \$130.00		
CLAIMS	NUMBER FILED		NUMBER EXTRA		RATE			
Total claims	21	- 20 =	1	x	\$50.00	\$ \$50.00		
Independent clair	ms 5	- 3=	2	x	\$200.00	\$ \$400.00		
MULTIPLE DEPE	ENDENT CLAIMS (i	f applicable)	⊠	+	\$360.00	\$ \$360.00		
TOTAL OF ABOVE CALCULATIONS =						\$ \$1,940.00		
Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by 1/2.						\$ \$0.00		
SUBTOTAL =						\$ \$1,940.00		
Processing fee of \$130.00 for furnishing the English translation later than 30 months from the earliest claimed priority date (37 CFR 1.492(f)).						\$ . \$0.00	r	
TOTAL NATIONAL FEE =						\$ \$1,940.00		
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40 per property +						\$ \$0.00		
TOTAL FEES ENCLOSED =						\$ \$1,940.00		
Amount to be refunded:							\$	
Amount to be charged:							\$	
a. 🔀 A check in the amount of \$ \$1,940.00 to cover the above fees is enclosed.								
b. Please charge my Deposit Account No in the amount of to cover the above fees.  A duplicate copy of this sheet is								
c.   The Director is hereby authorized to charge any additional fees which may be required, or credit any overpayment								
to Deposit Account No. <u>03-1664</u> . A duplicate copy of this sheet is enclosed.								
d. Fees are to be charged to a credit card. WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.								
NOTE: Where an appropriate time limit under 37 CFR 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the International Application to pending status.								
SEND ALL CORRESPONDENCE TO:						7_		
Novartis Vaccines and Diagnostics Inc SIGNA					SIGNATURE	JRE		
Corporate Intellectual Property R338  Helen Lee								
P.O. Box 8097								
Emeryvine, Camornia 94002-0097								
US Customer Number 27476  39,270  DECUSTOR:								
REGISTRAT						TION NUMBER		

PATENT PP022717.0004

## IAP16 Rec'd PCT/PTO 14 SEP 2006

## PATENT COOPERATION TREATY IN THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US)

International Application No. PCT/IB2005/000987

International Filing Date 17 March 2005

**Priority Date Claimed** 

17 March 2004

Title of Invention

ANALYSIS OF SACCHARIDE VACCINES WITHOUT INTERFERENCE

Applicants for DO/EO/US:

Angela BARDOTTI, Daniela PROIETTI and Stefano RICCI

## CERTIFICATE OF MAILING BY EXPRESS MAIL

Mail Stop PCT Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Express Mail Mailing Label No.: EL987062178US

Date of Deposit: 15 September 2006

I hereby certify that the attached Transmittal Letter to the United States Designated/Elected Office (DO/EO/US) Concerning a Filing Under 35 U.S.C.371, copy of unsigned Declaration for Patent Application, copy of Published Specification, International Search Report, Check No. 9151 in the amount \$1940 and Postal Receipt Card are being deposited with the United Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R.1.10 on the date indicated above and addressed to the Mail Stop PCT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Date: 15 September 2006

Melodi Dice

Novartis Vaccines and Diagnostics, Inc 4560 Horton Street Emeryville, California 94608 United States of America